The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Amyloid β peptide ratio 42/40 but not Aβ42 correlates with phospho‐Tau in patients with low‐ and high‐CSF Aβ40 load
Open accessAbstract
Neurochemical dementia diagnostics (NDD) can significantly improve the clinically based categorization of patients with early dementia disorders, and the cerebrospinal fluid (CSF) concentrations of amyloid β peptides ending at the amino acid position of 42 (Aβx‐42 and Aβ1‐42) are widely accepted biomarkers of Alzheimer’s disease (AD). However, in subjects with constitutively high‐ or low‐CSF concentrations of total Aβ peptides (tAβ), the NDD interpretation might lead to erroneous conclusions as these biomarkers seem to correlate better with the total Aβ load than with the pathological status of a given patient in such cases. In this multicenter study, we found significantly increased CSF concentrations of phosphorylated Tau (pTau181) and total Tau in the group of subjects with high CSF Aβx‐40 concentrations and decreased Aβx‐42/x‐40 concentration ratio compared with the group of subjects with low CSF Aβx‐40 and normal Aβ ratio (p < 0.001 in both cases). Furthermore, we observed significantly decreased Aβ ratio (p < 0.01) in the group of subjects with APOE ε4 allele compared with the group of subjects without this allele. Surprisingly, patients with low‐Aβx‐40 and the decreased Aβ ratio characterized with decreased pTau181 (p < 0.05), and unaltered total Tau compared with the subjects with high Aβx‐40 and the Aβ ratio in the normal range. We conclude that the amyloid β concentration ratio should replace the ‘raw’ concentrations of corresponding Aβ peptides to improve reliability of the neurochemical dementia diagnosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Buée, L., Bussière, T., Buée-Scherrer, V., Delacourte, A., & Hof, P. R. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(00)00019-9 · Cited by 2,015
CSF markers for incipient Alzheimer's disease
Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291
Self-citationJorm, A. F. (1994) · Psychological Medicine · doi:10.1017/s003329170002691x · Cited by 1,204
Antibodies against β-Amyloid Slow Cognitive Decline in Alzheimer's Disease
Hock, C., Konietzko, U., Streffer, J. R., Tracy, J., Signorell, A., Müller-Tillmanns, B., Lemke, U., Henke, K., Moritz, E., Garcia, E., et al. (2003) · Neuron · doi:10.1016/s0896-6273(03)00294-0 · Cited by 777
Improved discrimination of AD patients using β-amyloid (1-42) and tau levels in CSF
Hulstaert, F., Blennow, K., Ivanoiu, A., Schoonderwaldt, H. C., Riemenschneider, M., Deyn, P. P. D., Bancher, C., Cras, P., Wiltfang, J., Mehta, P. D., et al. (1999) · Neurology · doi:10.1212/wnl.52.8.1555 · Cited by 724
Self-citationConsensus Report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease”
(1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00022-0 · Cited by 666
The challenge of time: Clock‐drawing and cognitive function in the elderly
Shulman, K. I., Shedletsky, R., & Silver, I. L. (1986) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.930010209 · Cited by 540
Vanmechelen, E., Vanderstichele, H., Davidsson, P., Van Kerschaver, E., Van Der Perre, B., Sjögren, M., Andreasen, N., & Blennow, K. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01036-3 · Cited by 488
Ida, N., Hartmann, T., Pantel, J., Schrüder, J., Zerfass, R., Fürstl, H., Sandbrink, R., Masters, C. L., & Beyreuther, K. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.37.22908 · Cited by 478
Self-citationThe Bayer Activities of Daily Living Scale (B-ADL)
Hindmarch, I., Lehfeld, H., de Jongh, P., & Erzigkeit, H. (1998) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000051195 · Cited by 453
Galasko, D., Chang, L., Motter, R., Clark, C. M., Kaye, J., Knopman, D., Thomas, R., Kholodenko, D., Schenk, D., Lieberburg, I., et al. (1998) · Archives of Neurology · doi:10.1001/archneur.55.7.937 · Cited by 442
Hampel, H., Buerger, K., Zinkowski, R., Teipel, S. J., Goernitz, A., Andreasen, N., Sjoegren, M., DeBernardis, J., Kerkman, D., Ishiguro, K., et al. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.1.95 · Cited by 434
Self-citationNeurochemical diagnosis of Alzheimer’s dementia by CSF Aβ42, Aβ42/Aβ40 ratio and total tau
Lewczuk, P., Esselmann, H., Otto, M., Maler, J. M., Henkel, A. W., Henkel, M. K., Eikenberg, O., Antz, C., Krause, W.-R., Reulbach, U., et al. (2004) · Neurobiology of Aging · doi:10.1016/s0197-4580(03)00086-1 · Cited by 308
Self-citationHampel, H., Teipel, S. J., Fuchsberger, T., Andreasen, N., Wiltfang, J., Otto, M., Shen, Y., Dodel, R., Du, Y., Farlow, M., et al. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001473 · Cited by 287
Self-citationWiltfang, J., Esselmann, H., Bibl, M., Smirnov, A., Otto, M., Paul, S., Schmidt, B., Klafki, H. ‐., Maler, M., Dyrks, T., et al. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00818.x · Cited by 271
Self-citationItoh, N., Arai, H., Urakami, K., Ishiguro, K., Ohno, H., Hampel, H., Buerger, K., Wiltfang, J., Otto, M., Kretzschmar, H., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1054 · Cited by 256
Self-citationAncolio, K., Dumanchin, C., Barelli, H., Warter, J. M., Brice, A., Campion, D., Frébourg, T., & Checler, F. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.4119 · Cited by 180
Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers
Iqbal, K., Flory, M., Khatoon, S., Soininen, H., Pirttila, T., Lehtovirta, M., Alafuzoff, I., Blennow, K., Andreasen, N., Vanmechelen, E., et al. (2005) · Annals of Neurology · doi:10.1002/ana.20639 · Cited by 163
Wiltfang, J., Esselmann, H., Cupers, P., Neumann, M., Kretzschmar, H. A., Beyermann, M., Schleuder, D., Jahn, H., Rüther, E., Kornhuber, J., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m102790200 · Cited by 153
Self-citationWiltfang, J., Lewczuk, P., Riederer, P. F., Grünblatt, E., Hock, C., Scheltens, P., Hampel, H. J., Vanderstichele, H., Iqbal, K., Galasko, D. R., et al. (2005) · The World Journal of Biological Psychiatry · doi:10.1080/15622970510029786 · Cited by 136
Self-citationExpression of the Alzheimer protease BACE1 is suppressed via its 5'‐untranslated region
Lammich, S., Schöbel, S., Zimmer, A., Lichtenthaler, S. F., & Haass, C. (2004) · EMBO Reports · doi:10.1038/sj.embor.7400166 · Cited by 135
Wiltfang, J., Av, S., Schnierstein, B., Kelemen, G., Matthies, U., Klafki, H., Staufenbiel, M., Huether, G., Rüther, E., & Kornhuber, J. (1997) · Electrophoresis · doi:10.1002/elps.1150180332 · Cited by 131
Self-citationLewczuk, P., Esselmann, H., Bibl, M., Beck, G., Maler, J. M., Otto, M., Kornhuber, J., & Wiltfang, J. (2004) · Journal of Molecular Neuroscience · doi:10.1385/jmn:23:1-2:115 · Cited by 128
Self-citationLewczuk, P., Esselmann, H., Meyer, M., Wollscheid, V., Neumann, M., Otto, M., Maler, J. M., Rüther, E., Kornhuber, J., & Wiltfang, J. (2003) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.1048 · Cited by 108
Self-citationGenotype and phenotype in Alzheimer's disease
Holmes, C. (2002) · The British Journal of Psychiatry · doi:10.1192/bjp.180.2.131 · Cited by 104
Wiltfang, J., Arold, N., & NEUHOFF, V. (1991) · Electrophoresis · doi:10.1002/elps.1150120507 · Cited by 99
Self-citationLewczuk, P., Esselmann, H., Groemer, T. W., Bibl, M., Maler, J. M., Steinacker, P., Otto, M., Kornhuber, J., & Wiltfang, J. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2003.10.014 · Cited by 96
Self-citationβ‐amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt–Jakob disease
Wiltfang, J., Esselmann, H., Av, S., Bibl, M., Cepek, L., Steinacker, P., Mollenhauer, B., Büerger, K., Hampel, H. J., Paul, S., et al. (2003) · Annals of Neurology · doi:10.1002/ana.10661 · Cited by 91
Self-citationConcentrations of amyloid β protein in cerebrospinal fluid of patients with alzheimer's disease
van Gool, W. A., Walstra, G. J. M., Bolhuis, P. A., Kuiper, M. A., & Wolters, E. C. (1995) · Annals of Neurology · doi:10.1002/ana.410370221 · Cited by 82
Schönknecht, P., Pantel, J., Hunt, A. M., Volkmann, M., Buerger, K., Hampel, H., & Schröder, J. (2003) · Neuroscience Letters · doi:10.1016/s0304-3940(02)01481-7 · Cited by 68
Self-citationElectrophoretic separation of amyloid β peptides in plasma
Lewczuk, P., Esselmann, H., Bibl, M., Paul, S., Svitek, J., Miertschischk, J., Meyrer, R., Av, S., Maler, J. M., Klein, C., et al. (2004) · Electrophoresis · doi:10.1002/elps.200406068 · Cited by 66
Self-citationCerebrospinal fluid τ and β-amyloid(1-42) in dementia disorders
Vanmechelen, E., Vanderstichele, H., Hulstaert, F., Andreasen, N., Minthon, L., Winblad, B. G., Davidsson, P., & Blennow, K. (2001) · Mechanisms of Ageing and Development · doi:10.1016/s0047-6374(01)00304-9 · Cited by 51
Evaluation and Use of Diagnostic Tests in Alzheimer’s Disease
Mayeux, R. P. (1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00014-1 · Cited by 39
Vanmechelen, E., Kerschaver, E. V., Blennow, K., Deyn, P. P. D., Galasko, D. R., Parnetti, L., Sindic, C. J. M., Arai, H., Riemenschneider, M. J., Hampel, H. J., et al. (2001) · Wiley eBooks · doi:10.1002/0470846453.ch26 · Cited by 23
Self-citation
Cited by
Knopman, D. S., Amieva, H., Petersen, R. C., Chételat, G., Holtzman, D. M., Hyman, B. T., Nixon, R. A., & Jones, D. T. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00269-y · Cited by 2,606
Biomarkers for Alzheimer's disease: current status and prospects for the future
Blennow, K., & Zetterberg, H. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12816 · Cited by 1,000
A new era for understanding amyloid structures and disease
Iadanza, M. G., Jackson, M. P., Hewitt, E. W., Ranson, N. A., & Radford, S. E. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0060-8 · Cited by 980
Hansson, O., Lehmann, S., Otto, M., Zetterberg, H., & Lewczuk, P. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0485-0 · Cited by 585
Self-citationCurrent state of Alzheimer’s fluid biomarkers
Molinuevo, J. L., Ayton, S., Batrla, R., Bednar, M. M., Bittner, T., Cummings, J., Fagan, A. M., Hampel, H., Mielke, M. M., Mikulskis, A., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1932-x · Cited by 518
Self-citation
Metadata
- Authors
- Wiltfang, J., Esselmann, H., Bibl, M., Hüll, M., Hampel, H., Kessler, H., Frölich, L., Schröder, J., Peters, O., Jessen, F., Luckhaus, C., Perneczky, R., Jahn, H., Fiszer, M., Maler, J. M., Zimmermann, R., Bruckmoser, R., Kornhuber, J., & Lewczuk, P.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2006-12-05
- Volume
- 101
- Issue
- 4
- Pages
- 1053-1059
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W2144647267
- Cited by
- 263
- References
- 37
- FWCI
- 4.31
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.